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Background: Mucormycosis incidence is increasing and is associated with a high rate of mortality. Although lipid-
based formulations of amphotericin B are the recommended first-line treatment, only one prospective trial in a
limited number of patients has been performed to evaluate this regimen.
Methods: Patients with proven or probable mucormycosis were included between June 2007 and March 2011.
Patients were scheduled to receive 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month
and surgery was performed when appropriate. The primary outcome was response rate at week 4 or at the end of
treatment (EOT) if before week 4, evaluated by an independent committee. ClinicalTrials.gov Identifier:
NCT00467883.
Results: Forty patients were enrolled. Response was analysed in 33 patients at week 4. Most patients had a haem-
atological malignancy as their primary underlying disease (53%). Seventy-one percent of patients underwent
therapeutic surgery. The response rate at week 4 or at EOT was 36%, with 18% partial responses and 18% com-
plete responses. The response rate at week 12 was 45%, with 13% partial responses and 32% complete
responses. Overall mortality was 38% at week 12 and 53% at week 24. Serum creatinine doubled in 16 (40%)
patients and returned to normal levels within 12 weeks in 10/16 (63%).
Conclusions: High-dose L-AMB for mucormycosis, in combination with surgery in 71% of cases, was associated
with an overall response rate of 36% at week 4 and 45% at week 12 and creatinine level doubling in 40% of
patients (transient in 63%). These results may serve as the basis for future clinical trials.
Introduction
Mucormycosis is a life-threatening fungal infection that is emerging
worldwide,1–6 occurring primarily in patients with haematological
malignancies (HMs), diabetes mellitus (DM), solid organ trans-
plantation and trauma with skin-penetrating injuries. Mucorales
are ubiquitous filamentous virulent fungi intrinsically resistant to
various antifungals. Moreover, high Mucorales angiotropism
causes major necrosis,7 which results in limited antifungal diffu-
sion to the infection site. Amphotericin B, itraconazole, posacon-
azole and isavuconazole are the only antifungal agents active
against Mucorales.8,9 However, itraconazole, posaconazole and
even isavuconazole are not active against all Mucorales species.9
Therapeutic data on mucormycosis are scarce, limited to two pro-
spective trials evaluating the efficacy of the combination of a
polyene [liposomal amphotericin B (L-AMB)] and deferasirox as
first-line treatment10 and, recently, of isavuconazole as first-line
or salvage treatment.11 First results of this open-label, non-
comparative study evaluating isavuconazole as first-line therapy
in mucormycosis led to its recent FDA approval and EMA evalu-
ation.11 Amphotericin B deoxycholate treatment is complicated
by unacceptably high rates of toxicity. Several retrospective trials
have assessed the efficacy of lipid-based amphotericin B formula-
tions in mucormycosis treatment, confirming their improved
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safety profile.12 – 17 In addition, a higher efficacy of high-dose
L-AMB in mucormycosis mouse models has been shown:
10 mg/kg/day L-AMB was more effective than 5 or 1 mg/kg/day
in reducing Rhizopus arrhizus fungal burden and led to higher
lung tissue concentrations.18 Furthermore, in a 44 patient Phase
I–II trial comparing several dose regimens, i.e. 7.5, 10, 12.5 and
15 mg/kg/day L-AMB, the highest amphotericin B plasma concen-
tration was obtained with 10 mg/kg/day as well as the highest
mean AUC at 24 h.19 While high-dose L-AMB is recommended
for visceral leishmaniasis treatment,20 it is associated with
increased toxicity without better efficacy in invasive pulmonary
aspergillosis.21 Because of the severity of mucormycosis and cau-
tiously promising evidence from pre-clinical data, in spite of the
increased toxicity of a 10 mg/kg/day dose, we believed it was war-
ranted to evaluate the efficacy and tolerance of high-dose L-AMB
in the initial treatment of mucormycosis. We therefore conducted
a prospective, multicentre, pilot trial to evaluate the efficacy and
safety of high-dose (10 mg/kg/day) L-AMB monotherapy for initial
mucormycosis treatment.
Methods
Trial design
The AmBizygo trial was a multicentre, national, prospective, pilot study
conducted in 63 centres in France from June 2007 to July 2011 to evaluate
the efficacy and safety of high-dose (10 mg/kg/day) L-AMB for the initial
treatment of mucormycosis (NCT00467883). An ethics committee (CPP
Comite´ de Protection des Personnes Ile de France II) approved the proto-
col. Written informed consent was obtained from each patient enrolled in
the trial. Patient follow-up occurred at week 1, week 2, week 4 (W4), end of
treatment (EOT) if treatment ended before W4, week 12 (W12) and week
24 (W24). Survival was assessed at 12 months.
Study participants
Eligible patients had proven or probable mucormycosis according to
European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and NIAID Mycoses Study Group cri-
teria without any age restrictions.22 Mucormycosis was proven by the pres-
ence of large and non-/poorly septate hyphae consistent with Mucorales on
tissue biopsy or Mucorales in culture from a sterile site. Mucormycosis was
considered probable when Mucorales were found in culture associated with
clinical or radiological abnormalities compatible with an invasive fungal
infection, regardless of underlying disease of the patient. An independent
expert committee (P. R., M. W. and S. P.) reviewed all charts and classified
the cases by consensus into the above diagnostic categories. All the avail-
able isolates were sent to the National Reference Center for Invasive
Mycoses and Antifungals, Institut Pasteur for phenotypic and molecular
identification and in vitro susceptibility testing according to EUCAST meth-
odology. Exclusion criteria were life expectancy,72 h, pregnancy, breast-
feeding, severe allergy to polyene and a previous curative amphotericin B
or posaconazole treatment .5 days during the previous month. An inde-
pendent safety committee monitored the trial. Corticosteroids were con-
sidered a risk factor if patients received≥0.3 mg/kg/day for.3 weeks and
neutropenia was considered a risk factor if counts were ,500 cells/mm3
over 10 days in the previous month. Definition of the main risk factors and
location of mucormycosis was as reported previously.2
Treatment
After inclusion, patients received L-AMB (AmBisomew, Gilead Sciences,
Boulogne-Billancourt, France) at high dose (10 mg/kg/day) for 4 weeks
along with surgical therapy when deemed necessary. Surgical procedures
were designed according to local extent of disease and decision of the sur-
geon. L-AMB was given as an infusion over ≥2 h. If any reaction was
noticed, infusion duration could be extended. No recommendation on
fluids or pre-medication was given. In patients in whom there was doub-
ling of serum creatinine levels as compared with baseline, it was recom-
mended that the L-AMB dose be reduced to 7.5 mg/kg/day. If creatinine
values did not improve within 3 days, L-AMB dosing was further reduced
to 5 mg/kg/day. Safety monitoring included serum creatinine, magne-
sium, potassium, AST, ALT, GGT and blood cell counts (baseline, twice
weekly for the first 2 weeks and then weekly) as well as possible concomi-
tant nephrotoxic drugs. Creatinine values were monitored at 3 months.
Treatment was stopped in cases of anaphylactic reactions or if there
was an increase in liver enzymes .20 times normal levels.
Primary and secondary outcomes
Clinical, radiological and mycological responses were assessed at W4 or at
EOT if it occurred before W4. Response was also evaluated at W12. A cen-
tralized analysis of all radiological studies was performed. Overall response
was evaluated according to the previously described Herbrecht criteria23
and the Segal criteria,24 published after the beginning of the present
study. Response was assessed by the previously mentioned independent
expert committee. Complete and partial responses were considered
favourable responses, whereas stable disease and response failure were
considered unfavourable. Death of any cause was considered a failure.
Patient follow-up lasted for 48 weeks. Disseminated infection was defined
by at least two non-contiguous sites of infection.
The primary endpoint was the percentage of overall favourable
responses (complete or partial response) at W4 or before if treatment
ended earlier, according to the Herbrecht evaluation criteria. The endpoint
was chosen because the study treatment duration was 4 weeks.
Non-evaluable patients were not included in response evaluation.
Secondary endpoints were treatment efficacy at W12, survival and relapse
at 6 and 12 months and safety. Mucormycosis-related deaths were
defined as deaths occurring when the mucormycosis infection was still
considered to be progressing and when there was no alternative cause,
as decided by the independent expert committee.
Statistical analyses
Sample size was calculated based on an estimate of the efficacy of L-AMB
monotherapy in the treatment of mucormycosis. On the basis of an
expected primary event rate of 30%, we estimated that enrolment of 36
patients would provide a precision equal to+15%. To take into account the
possibility of non-evaluable patients, the initial sample size was increased
to 44 subjects. The efficacy analysis was performed on all evaluable
patients for whom diagnosis was confirmed by the expert panel and
who had not received previous antifungal treatment with anti-Mucorales
activity as per the exclusion criteria. The safety analysis was performed on
all included patients. Efficacy was expressed as a percentage with the 95%
CI calculated using a binomial method. Relationships between categorical
variables were tested with the x2 test or Fisher’s exact test. Student’s t-test
was used to compare continuous variables between two groups. Survival
time was measured from the date of entry into the study to the date of
death or last follow-up. Survival curves were estimated using the
Kaplan–Meier method. Prognostic effect of clinical or biological factors
was estimated using the log-rank test or univariate Cox model. All statis-
tical analyses were performed using R software (http://cran.r-project.org).
Results
Patients
Forty patients were included between June 2007 and March 2011,
including two children under the age of 16 years. Six patients were
High-dose L-AMB for mucormycosis
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excluded because they did not meet the eligibility criteria, i.e.
recent antifungal treatment active against Mucorales (n¼1) or
mucormycosis diagnosis excluded by the expert panel evaluation
(n¼5). Thirty-four patients had mucormycosis and all inclusion
criteria. Twenty-nine patients (85%) had proven infection (25
with positive histology and 4 with positive Mucorales culture
from a sterile site) (Figure 1). Five patients had probable infection
with positive culture from a non-sterile site with signs of infection
(four positive cultures were associated with positive microscopic
examination). The patient characteristics are detailed in Table 1.
Most patients had an underlying HM as their main risk factor
(53%). In the patients with HM, 28% underwent HSCT, 17% had
graft versus host disease, 44% received corticosteroids and 33%
had recent neutropenia. Eighteen percent of patients had DM (two
patients had type I DM and four had type II DM) and in 9% trauma
was the main risk factor. Nine patients had BMI.25 kg/m2 and 2
had BMI .30 kg/m2.
Infection location included lung only (29%), rhino-orbito-cerebral
only (26%) or skin only (18%) and was disseminated in 18% of
cases. Other locations included gastrointestinal (n¼1), liver (n¼1)
and larynx (n¼1). Mucormycosis location varied with underlying dis-
ease: HM was associated with disseminated or lung infections and
DM with rhino-orbito-cerebral infections (P¼0.018). Among
rhino-orbito-cerebral infections, 3/9 patients had DM and 5/9
had HM; among lung infections, 7/10 had HM and 2/10 DM; and
among disseminated infections, 4/6 had HM. Eight patients had
developed another invasive fungal infection during the 3 months
prior to mucormycosis diagnosis [invasive candidiasis (n¼4) and
invasive aspergillosis (n¼4)]. Twenty-nine patients had received at
least one antifungal drug during the month before diagnosis [posa-
conazole (n¼6), polyenes (n¼21) for ,5 days, fluconazole (n¼7),
n = 6
Eligibility
violation*
n = 34
Positive
histology
n = 25
Positive
culture
n = 15
Negative
culture
n = 7
Culture ND
n = 3
Negative histology†
n = 9
6 ND, 3 negative
Positive
culture
n = 5
Positive microscopic
examination
n = 4
Positive culture from
sterile site
n = 4‡
N = 40
Figure 1. Mucormycosis diagnosis. *Recent antifungal treatment active against Mucorales (n¼1) or mucormycosis diagnosis excluded according to the
expert panel evaluation (n¼5). †Negative or not done (ND). ‡Bile duct, muscle, bone or pleural fluid. Light grey shading indicates proven mucormycosis
and dark grey shading indicates probable mucormycosis.
Table 1. Characteristics of the 34 analysed patients
Patients’ characteristics No. (%) or median (range)
Male 21 (62)
Age (years) 53 (0.50–78.10)
Time from symptom onset to
treatment (days)
46 (4–344)
Underlying disease
HM 18 (53)
haematopoietic stem cell transplant 5/18 (28)
GVHD 3/18 (17)
neutropenia 6/18 (33)
corticosteroids 8/18 (44)
DM 6 (18)
trauma 3 (9)
solid organ transplant 3 (9)
othera 4 (12)
Site of infection
lung 10 (29)
rhino-orbito-cerebral 9 (26)
skin 6 (18)
disseminated 6 (18)
otherb 3 (9)
GVHD, graft versus host disease.
aPrematurity (n¼1), cancer (n¼1), no risk factor (n¼ 1) and diabetic
ketoacidosis (n¼1).
bGastrointestinal (n¼1), liver (n¼1) and larynx (n¼1).
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voriconazole (n¼11) and echinocandin (n¼13)]. Thirteen patients
had breakthrough infections: nine occurred in patients treated
with voriconazole and four with caspofungin. No patients presented
reverse halo sign on chest CT scan.
Phenotypic and molecular characterization of Mucorales strains
was performed for 23 strains out of 24. The main species identified
were Lichtheimia corymbifera (22%), Lichtheimia ramosa complex
(35%) and R. arrhizus (18%). Other species identified were
Rhizomucor pusillus (9%), Saksenaea vasiformis (4%) and
Cunninghamella elegans (4%). No molecular identification could
be performed for one strain.
Treatment
Study treatment is detailed in Table 2. Twenty-four patients (71%)
underwent surgical procedures (diagnostic surgery not included),
including 18 (53%) before initiation of L-AMB therapy. Twelve
patients had one therapeutic surgical procedure, six had two surgical
procedures and six had three surgical procedures. All nine patients
with rhino-orbito-cerebral infection underwent surgery, two (20%)
with lung infections, five (83%) with skin infections and five (83%)
with disseminated infections [kidney resection (n¼2), soft tissue
resection (n¼2) and digestive tract and liver surgery (n¼1)].
Surgical procedures were mainly performed before L-AMB treatment:
67% in rhino-orbito-cerebral cases, all cases of lung infection, 60%
for skin infections and 80% for disseminated infections. One patient
with laryngeal infection as well as a patient with liver involvement
underwent surgery. Median time between first symptoms and
L-AMB initiation was 46 days (4–367). One patient had telluric
trauma 367 days before mucormycosis diagnosis and was infected
by S. vasiformis. Twenty-nine (85%) patients received 10 mg/kg
L-AMB on the first day of study inclusion and 21 patients (62%)
received 10 mg/kg/day during the first 7 days. Median L-AMB mono-
therapy duration was 21 days (0–28). One patient received 5 days
of L-AMB before inclusion and a combination of L-AMB and posacon-
azole after inclusion. Median cumulative L-AMB dose was 161 mg/kg
(0 –320). Median dose per treatment day was 9.5 mg/kg/day
(5–11.4). L-AMB was administered at a 10 mg/kg/day dosing for
a median of 13.5 days (0–28).
Primary endpoint
Treatment responses according to Herbrecht criteria are detailed
in Table 3. Thirty-three out of the 34 patients were evaluated at
W4 or at EOT when it occurred earlier. One patient was considered
non-evaluable because they had no evaluation of radiological
response at W4, whereas the clinical response was complete.
Twelve patients (36%, 95% CI 20% –55%) had a favourable
response at W4 or at EOT if earlier. Six patients (18%) had a com-
plete response and 6 a partial response; 4 patients had stable dis-
ease (12%), 10 failed treatment and survived (30%) and 7 died
(21%). Focusing specifically on the L-AMB dose, the W4 response
rate was 43% (9/21) in patients who received 10 mg/kg/day dur-
ing the first week compared with 25% (3/12) in patients who did
Table 2. Study treatment
Treatment
No. (%) or
median (range)
L-AMB monotherapy duration (days)a 21 (0–28)
L-AMB monotherapy cumulative dose (mg/kg) 161 (0–320)
L-AMB daily dose (mg/kg) 9.5 (5.0–11.4)
10 mg/kg/day L-AMB duration (days) 13.5 (0–28)
Surgical procedureb 24 (71)
Surgical procedure before L-AMB treatmentb 18 (53)
Number of surgical proceduresb
one 12 (50)
two 6 (25)
three 6 (25)
aOne patient received additional treatment with posaconazole after
inclusion.
bCount excluding diagnostic surgery.
Table 3. Treatment response according to Herbrecht and Segal criteria
Herbrecht, W4 or EOT if
before (n¼33)a
Segal, W4 or EOT if
before (n¼32)b
Herbrecht, W12
(n¼31)c
Segal, W12
(n¼31)c W24
Favourable response 12/33 (36%) 10/32 (31%) 14/31 (45%) 15/31 (48%) NA
partial response 6/33 (18%) 4/32 (13%) 4/31 (13%) 6/31 (19%) NA
complete response 6/33 (18%) 6/32 (19%) 10/31 (32%) 9/31 (29%) NA
Failure 21/33 (64%) 22/32 (69%) 17/31 (55%) 16/31 (52%) NA
stable 4/33 (12%) 7/32 (22%) 2/31 (6%) 1/31 (3%) NA
failure without death 10/33 (30%) 8/32 (25%) 2/31 (6%) 2/31 (6%) NA
deathd 7/34 (21%) 7/34 (21%) 13/34 (38%) 13/34 (38%) 18/34 (53%)
related to mucormycosis 5/34 (15%) 9/34 (26%) 10/34 (29%)
not related to mucormycosis 2/34 (6%) 4/34 (12%) 8/34 (24%)
NA, not available.
aResponse was evaluated for 33 patients as 1 patient was non-evaluable at W4.
bResponse was evaluated for 32 patients as 2 patients were non-evaluable at W4.
cResponse was evaluated for 31 patients as 3 patients were non-evaluable at W12.
dDeath was evaluated for the 34 patients with mucormycosis.
High-dose L-AMB for mucormycosis
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not. Although not statistically significant, the W4 response rate
was 43% (12/28) in patients who received≥7.5 mg/kg/day during
the first week compared with 0% (0/5) in patients who did not.
Age, gender, risk factor, location, risk factor number, surgery,
weight and delay between first symptoms and treatment were
not associated with response at W4 or at EOT when it occurred
earlier.
Secondary endpoints
Fourteen out of 31 evaluable patients (45%, 95% CI 27%–64%)
had a favourable response at W12. Three patients were consid-
ered non-evaluable because radiological evaluation was not per-
formed; however, clinical response was complete. These three
patients were therefore not included in the response analysis.
Ten patients had a complete response (32%), 4 had partial
responses (13%), 2 were stable, 2 failed but survived and 13
patients died, 6 between W4 and W12. Treatment response eval-
uated according to Segal’s criteria was 31% (16%–50.0%) at W4
(32 evaluable patients) and 48% (31%–67%) at W12 (31 evalu-
able patients).
At W24, survival was 47% (95% CI 33%–67%) (Figure 2a); 18
patients died, 10 with mucormycosis (Figure 3). Mortality rates
at W4, W12, W24 and 12 months were 21%, 38%, 53% and
53%, respectively. No deaths or relapses were observed between
W24 and 12 months. Among age, gender, weight, infection loca-
tion, risk factor number and duration between first symptoms
and treatment, the only factor associated with mortality was
HM or cancer [HR¼3.15 (1.12 – 8.91), P¼0.02; Figure 2b].
Patients who received 10 mg/kg/day L-AMB during the first 7
days compared with those who did not had similar mortality
rates [1.07 (0.40–2.85), P¼0.91]. No difference was observed
for those who received ≥7.5 mg/kg/day during the first 7 days
of treatment compared with those who did not [HR¼0.67
(0.19–2.33), P¼0.52]. No deaths were observed between W24
and W48.
Safety
The safety analysis population was 40 patients. Adverse events
related to L-AMB are detailed in Table 4. Creatinine levels doubled
compared with baseline in 40% (16/40) of patients, leading to
dose reduction in 7 patients, treatment interruption in 5 and
definitive treatment discontinuation for 1 patient. Creatinine
doubling occurred in 58% (7/12) of patients with DM compared
with 32% (9/28) of patients without DM (P¼0.17). Three months
after EOT, among the 16 patients who doubled their creatinine
levels, 10 (63%) recovered normal kidney function, 4 (25%) died
before 3 months and 2 (12%) did not recover. Patients presented
with the following adverse events: 2 (5%) had hypokalaemia
,2.5 mmol/L and 16 (40%) ,3 mmol/L, 10 (25%) had gastro-
intestinal side effects, 5 (12%) exanthema, 4 (10%) transaminase
elevation, 6 (15%) cholestasis, 1 (2%) lumbar pain, 3 (7%) low
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blood pressure during infusion, 3 (7%) fever and 7 (17%) cyto-
penia. Ten adverse events resulted in treatment interruption.
Thirty-seven severe adverse events were reported from
26 patients; 14 were considered related to L-AMB.
Discussion
We report the largest prospective clinical trial performed to date
in the treatment of mucormycosis. Most data available currently
in the field of mucormycosis treatment are retrospective and
have several limitations, i.e. inclusion criteria, confounding bias
and response evaluation. In the present, trial inclusion criteria
were not selective and all forms of mucormycosis were included,
regardless of the underlying disease, patient age and severity.
This study has several methodological strengths: (i) all diagnoses
were confirmed and all evaluations made by an independent
expert committee; (ii) most (85%) of the mucormycosis cases
were proven; (iii) patient characteristics and sites of infections
were representative of those found in recent retrospective stud-
ies (indeed, underlying disease and location were similar to those
obtained during the nationwide retrospective RetroZygo study
conducted in France between 2005 and 2007, which included
101 patients2); and (iv) identification to the genus and species
level was assessed using molecular tools and morphology for
96% of the isolates in the national reference centre. The main
Mucorales species identified in this study were Lichtheimia spp.
compared with R. arrhizus in the RetroZygo study.2 Lichtheimia
spp. represented 29% of strains in the latter study. The high num-
ber of patients with proven mucormycosis, the absence of
reverse halo sign and the limited number of patients that
received mucormycosis treatment during the first 2 weeks after
the occurrence of first symptoms probably depict the delayed
diagnosis.
Our main finding was that a therapeutic strategy combining
high-dose L-AMB and surgery (performed in 71% of patients)
was associated with a 36% response rate at W4. These results
can be compared with the Defeat study, which is the only pub-
lished prospective therapeutic trial in mucormycosis10 where 20
patients were treated with L-AMB at a minimum dose of 5 mg/kg
with either deferasirox or placebo, in combination with surgical
debridement in all patients. W4 response rates were similar in
both studies with a 36% response rate in the AmBizygo study
and 40% global success in the Defeat study. W12 response
rates were higher in the AmBizygo study with a 45% response
rate compared with 35% global success reported in the Defeat
study. W12 mortality was 42% PP in the Defeat study compared
with 38% in the AmBizygo study. More recently, the first results of
an open-label, non-comparative study evaluating isavuconazole
as first-line therapy in 21 patients with mucormycosis showed a
response in 31.6% at EOT while survival was 66.7% at week 6
(W6) and 57.1% at W12.11 Based on those data, isavuconazole
was approved by the FDA as first-line treatment of mucormycosis.
Therefore, despite the lack of any comparative study, the W12
response rate was 45% with high-dose L-AMB in the AmBizygo
trial compared with 31.6% at end of first-line treatment with isa-
vuconazole (median time of 102 days) in the VITAL study.11
Furthermore, isavuconazole MIC values for Mucorales species
are higher than those of amphotericin B25 and, finally, data on isa-
vuconazole penetration in the CNS are scarce. Among the 18
patients who died during study follow-up, mucormycosis-related
Table 4. Adverse events related to L-AMB
No. (%) Dose reduction Treatment interruption Definitive treatment interruption Serious adverse events
Doubling of creatinine levela 16 (40) 7 (17) 5 (12) 1 (2) 4 (10)
Potassium level
,2.5 mmol/L 2 (5) 0 0 0 1 (2)
,3 mmol/Lb 16 (40) 1 (2) 0 0 2 (5)
Gastrointestinal 10 (25) 0 2 (5) 0 1 (2)
Rash 5 (12) 1 (2) 0 0 1 (2)
Elevation of liver enzymesc 4 (10) 1 (2) 1 (2) 0 0
Cholestasis 6 (15) 1 (2) 1 (2) 1 (2) 1 (2)
Lumbar pain 1 (2) 1 (2) 0 0 1 (2)
Hyperglycaemia 1 (2) 0 0 0 1 (2)
Catheter thrombosis 1 (2) 0 0 0 1 (2)
Low blood pressure 3 (7) 0 0 0 0
Fever 3 (7) 0 1 (2) 0 0
Cytopenia 7 (17) 1 (2) 0 1 (2) 1 (2)
aCreatinine level two times the baseline level.
bIncludes those with hypokalaemia ,2.5 mmol/L.
cDefined by the investigator.
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mortality occurred mainly during the first 3 months after diagno-
sis (10 patients died from mucormycosis: 5 during the first month;
4 between months 1 and 3; and 1 between months 3 and 6).
These results are concordant with those reported by Xhaard
et al.,26 who reported 59% mortality occurring before day 115
among 29 cases of mucormycosis in allo HSCT patients.
Several methodological conclusions, potentially useful for fur-
ther trials, can be drawn from our results. Interestingly, for the first
time, we had the opportunity to evaluate patient responses using
both Herbrecht23 and Segal24 criteria. W4 response was 36%
according to Herbrecht criteria versus 31% according to Segal cri-
teria, while W12 response was 45% versus 48%, respectively,
thereby showing concordant results between the two criteria.
The optimal evaluation timepoint for assessment of antifungal
therapy in mucormycosis has not been defined. According to
Segal et al.,24 the optimal timepoint for evaluation in the treat-
ment of invasive aspergillosis is W6. In a study comparing
amphotericin B deoxycholate versus voriconazole in invasive
aspergillosis treatment, survival difference reached significance
at W6.23 W6 has also been chosen as the key timepoint
in a recent trial comparing voriconazole versus voriconazole
combined with anidulafungin in invasive aspergillosis.27
Response criteria are a composite of clinical, radiological and
mycological response. For lung lesions, CT scanning has a key
role. CT scan follow-up was well evaluated in invasive aspergillosis
with stable lesions at week 2 compared with initial CT.28 Legouge
et al.29 evaluated intensive CT follow-up in 16 patients with proven
pulmonary mucormycosis and found that mucormycosis lung
lesions continued to increase through day 26. Mucormycosis
radiological response is therefore slower than aspergillosis. Our
evaluation timing was chosen at W4 to coincide with the end of
study treatment. However, because mucormycosis radiological
evolution is slower than aspergillosis, the optimal timepoint to
evaluate response in mucormycosis most likely should be later
than for invasive aspergillosis and, based on our experience,
would be at W8. Therefore, stability or regression below 25% of
a lesion should be considered a positive response at W4.
Radiological evaluation in patients with rhino-orbito-
cerebral infections is difficult in patients who have undergone
surgery as it is challenging to distinguish active mucormycosis
lesions from surgical sequelae. In these cases, we found
the systematic evaluation of treatment response via naso-
fibroscopic evaluation and biopsies of great utility in assessing
clinical, endoscopic and mycological response. This manage-
ment will be evaluated prospectively in a national research pro-
ject (NCT02226705).
We also evaluated patient tolerance of the 4 week regimen
of high-dose L-AMB, which is twice the duration used in the
AmBiLoad trial. As expected, we report greater toxicity, with
higher rates of plasma creatinine level doubling (40% versus
31%). Of interest, renal toxicity tended to be more frequent in
patients with DM, probably related to diabetic nephropathy.
However, only 12% had persistent renal impairment 3 months
after the end of L-AMB therapy.
In conclusion, results of the AmBizygo study provide evidence
that high-dose L-AMB for mucormycosis, in combination with sur-
gery in 71% of cases, was associated with an overall response rate
of 36% at W4 and 45% at W12 and creatinine level doubling in
40% of patients (transient in 63%). These results may serve as
the basis for future clinical trials.
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